572 lines
30 KiB
HTML
572 lines
30 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>深度研报：中药公司创新转型</title>
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.10.1/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<style>
|
||
@import url('https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Noto Sans SC', sans-serif;
|
||
background-color: #000010;
|
||
overflow-x: hidden;
|
||
color: #E0E0E0;
|
||
}
|
||
|
||
.bg-deep-space {
|
||
position: fixed;
|
||
top: 0;
|
||
left: 0;
|
||
width: 100%;
|
||
height: 100%;
|
||
z-index: -1;
|
||
background-color: #000010;
|
||
overflow: hidden;
|
||
}
|
||
|
||
.light-orb {
|
||
position: absolute;
|
||
border-radius: 50%;
|
||
filter: blur(150px);
|
||
opacity: 0.3;
|
||
animation: move-orb 30s infinite alternate ease-in-out;
|
||
}
|
||
|
||
.orb-1 {
|
||
width: 800px;
|
||
height: 800px;
|
||
background: radial-gradient(circle, #0077ff, transparent 60%);
|
||
top: -20%;
|
||
left: -10%;
|
||
animation-duration: 35s;
|
||
}
|
||
|
||
.orb-2 {
|
||
width: 600px;
|
||
height: 600px;
|
||
background: radial-gradient(circle, #ff0077, transparent 60%);
|
||
bottom: -30%;
|
||
right: -20%;
|
||
animation-duration: 40s;
|
||
}
|
||
|
||
.orb-3 {
|
||
width: 700px;
|
||
height: 700px;
|
||
background: radial-gradient(circle, #390099, transparent 60%);
|
||
top: 20%;
|
||
right: -30%;
|
||
animation-duration: 30s;
|
||
animation-delay: -5s;
|
||
}
|
||
|
||
@keyframes move-orb {
|
||
0% {
|
||
transform: translate(0, 0) scale(1);
|
||
}
|
||
50% {
|
||
transform: translate(100px, 50px) scale(1.2);
|
||
}
|
||
100% {
|
||
transform: translate(-50px, -100px) scale(0.9);
|
||
}
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(10, 10, 25, 0.4);
|
||
backdrop-filter: blur(16px) saturate(180%);
|
||
-webkit-backdrop-filter: blur(16px) saturate(180%);
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
border-radius: 1.5rem; /* 24px */
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
transform: translateY(-5px) scale(1.01);
|
||
box-shadow: 0 0 30px rgba(0, 119, 255, 0.2), 0 0 40px rgba(255, 0, 119, 0.1);
|
||
border-color: rgba(255, 255, 255, 0.2);
|
||
}
|
||
|
||
.text-glow {
|
||
text-shadow: 0 0 8px rgba(0, 191, 255, 0.7), 0 0 16px rgba(0, 191, 255, 0.5);
|
||
}
|
||
|
||
.text-glow-pink {
|
||
text-shadow: 0 0 8px rgba(255, 105, 180, 0.7), 0 0 16px rgba(255, 105, 180, 0.5);
|
||
}
|
||
|
||
.section-title {
|
||
@apply text-3xl font-bold mb-6 text-glow tracking-wider text-center;
|
||
}
|
||
|
||
.bento-grid {
|
||
@apply grid grid-cols-1 lg:grid-cols-3 gap-6;
|
||
}
|
||
|
||
.bento-item {
|
||
@apply glass-card p-6 flex flex-col;
|
||
}
|
||
|
||
.bento-item-span-2 {
|
||
@apply lg:col-span-2;
|
||
}
|
||
.bento-item-span-3 {
|
||
@apply lg:col-span-3;
|
||
}
|
||
|
||
.bento-title {
|
||
@apply text-xl font-bold mb-4 text-glow-pink;
|
||
}
|
||
|
||
.bento-content ul {
|
||
@apply list-disc list-inside space-y-2 text-gray-300;
|
||
}
|
||
|
||
.bento-content li::marker {
|
||
color: #00BFFF;
|
||
}
|
||
|
||
.bento-content strong {
|
||
@apply font-semibold text-white;
|
||
}
|
||
|
||
table.glass-table {
|
||
border-collapse: separate;
|
||
border-spacing: 0;
|
||
width: 100%;
|
||
}
|
||
|
||
table.glass-table th, table.glass-table td {
|
||
@apply p-4 text-left border-b border-gray-700/50;
|
||
}
|
||
|
||
table.glass-table th {
|
||
@apply bg-transparent font-semibold text-glow-pink sticky top-0 backdrop-blur-sm z-10;
|
||
}
|
||
|
||
table.glass-table tr:hover {
|
||
background-color: rgba(255, 255, 255, 0.05);
|
||
}
|
||
|
||
table.glass-table ul {
|
||
@apply pl-4 my-2 space-y-2;
|
||
}
|
||
table.glass-table ul li {
|
||
@apply text-sm;
|
||
}
|
||
table.glass-table .stock-link {
|
||
@apply font-bold text-sky-400 hover:text-sky-300 transition-colors;
|
||
}
|
||
</style>
|
||
</head>
|
||
<body>
|
||
<div class="bg-deep-space">
|
||
<div class="light-orb orb-1"></div>
|
||
<div class="light-orb orb-2"></div>
|
||
<div class="light-orb orb-3"></div>
|
||
</div>
|
||
|
||
<div class="container mx-auto p-4 md:p-8">
|
||
|
||
<header class="text-center my-12">
|
||
<h1 class="text-5xl md:text-6xl font-extrabold text-glow tracking-widest uppercase">中药公司创新转型</h1>
|
||
<p class="mt-4 text-lg text-gray-400">从“价值压舱石”到“成长新引擎”的价值重估之路</p>
|
||
<p class="mt-8 text-xs text-gray-500">
|
||
北京价值前沿科技有限公司 AI投研agent：“价小前投研” 进行投研呈现
|
||
<br>
|
||
本报告为AI合成数据，投资需谨慎。
|
||
</p>
|
||
</header>
|
||
|
||
<main class="space-y-12">
|
||
|
||
<!-- Section 1: Core Insights & Market Dynamics -->
|
||
<section>
|
||
<div class="bento-grid">
|
||
|
||
<div class="bento-item bento-item-span-2">
|
||
<h2 class="bento-title">核心观点摘要</h2>
|
||
<div class="bento-content text-gray-300 space-y-4 text-base">
|
||
<p>“中药公司创新转型”正从防御性战略选择，演变为具备强大进攻性的产业趋势。其核心逻辑在于，传统中药企业正利用其稳健的<strong>现金流“压舱石”</strong>，通过内生研发与外延并购，系统性地布局高附加值的生物医药前沿领域，旨在实现从<strong>“稳定分红的价值股”</strong>向<strong>“具备高弹性空间的成长股”</strong>的价值重估（Re-rating）。</p>
|
||
<p>当前，该概念已越过纯粹的主题炒作，进入由临床数据和产品获批驱动的<strong>早期基本面验证阶段</strong>。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="bento-item">
|
||
<h2 class="bento-title">核心驱动力</h2>
|
||
<div class="bento-content">
|
||
<ul>
|
||
<li><strong>政策端“推力”</strong>：研发、审评、支付全链条支持。</li>
|
||
<li><strong>内生性“拉力”</strong>：传统业务遇瓶颈，寻求“第二增长曲线”。</li>
|
||
<li><strong>技术端“赋能”</strong>：AI与数字化融入，从“经验驱动”到“数据驱动”。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="bento-item bento-item-span-3">
|
||
<h2 class="bento-title">市场认知与预期差分析</h2>
|
||
<div class="bento-content grid grid-cols-1 md:grid-cols-3 gap-6">
|
||
<div>
|
||
<strong>预期差一：转型的广度与深度</strong>
|
||
<p class="mt-2 text-sm">市场普遍认知停留在“中药公司做创新药”，但忽略了<strong>“新质生产力”</strong>（如天士力的“数字中药”）、商业模式革新（如太极集团的品牌年轻化）及国企改革等多维变革的长期价值重塑作用。</p>
|
||
</div>
|
||
<div>
|
||
<strong>预期差二：资本效率与成功率</strong>
|
||
<p class="mt-2 text-sm">市场共识是“用中药现金流支持研发”，但低估了不同转型路径的风险。自主研发（康缘）风险高回报大；BD合作（华润三九）速度快但考验整合能力。市场尚未充分定价其中的风险差异。</p>
|
||
</div>
|
||
<div>
|
||
<strong>预期差三：中药现代化自身价值</strong>
|
||
<p class="mt-2 text-sm">市场焦点多集中于“跨界”的化药、生物药，可能低估了中药自身<strong>“二次开发”</strong>和<strong>“经典名方”</strong>产业化的潜力。这部分存量业务创新同样能带来巨大的估值弹性，但可能被市场所忽视。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Section 2: Data Visualization & Transformation Pathways -->
|
||
<section>
|
||
<div class="bento-grid">
|
||
<div class="bento-item bento-item-span-2">
|
||
<h2 class="bento-title">政策催化下的审评审批加速</h2>
|
||
<div id="approval-chart" class="w-full h-80"></div>
|
||
</div>
|
||
|
||
<div class="bento-item">
|
||
<h2 class="bento-title">关键转型路径</h2>
|
||
<div class="bento-content">
|
||
<ul>
|
||
<li><strong>战略跨界</strong>：“中药+”双轮驱动，布局化药、生物药、细胞/基因治疗等前沿领域。</li>
|
||
<li><strong>研发循证</strong>：用现代医学语言和循证医学证据证明疗效，进行二次开发与适应症拓展。</li>
|
||
<li><strong>技术赋能</strong>：引入AI大模型（如天士力与华为合作）辅助研发，生产线数字化智能化。</li>
|
||
<li><strong>商业创新</strong>：从渠道驱动转向学术营销与品牌重塑（如藿香正气水年轻化）。</li>
|
||
<li><strong>外延并购</strong>：通过BD合作与并购（如华润三九）快速获取创新管线。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Section 3: Catalysts, Future Path & Risks -->
|
||
<section>
|
||
<div class="bento-grid">
|
||
<div class="bento-item bento-item-span-2">
|
||
<h2 class="bento-title">未来发展路径与催化剂</h2>
|
||
<div class="bento-content space-y-4">
|
||
<div>
|
||
<h4 class="font-semibold text-white">近期催化剂 (3-6个月)</h4>
|
||
<ul class="text-sm">
|
||
<li><strong>政策落地</strong>：《医药工业数智化转型实施方案》正式发布。</li>
|
||
<li><strong>关键数据披露</strong>：众生药业、康缘药业等GLP-1类药物的II/III期临床数据。</li>
|
||
<li><strong>重磅产品获批</strong>：以岭药业苯胺洛芬、济川药业玛硒洛沙韦片等。</li>
|
||
<li><strong>医保目录调整</strong>：新获批创新药（如新天药业“龙苓胶囊”）能否成功纳入。</li>
|
||
</ul>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-white">长期发展路径</h4>
|
||
<ul class="text-sm">
|
||
<li><strong>第一阶段 (当前-2026)：验证期</strong> - 核心是临床数据与产品获批，完成从0到1。</li>
|
||
<li><strong>第二阶段 (2026-2028)：分化期</strong> - 成功者形成“中药现金牛+创新药引擎”，估值体系向Biopharma靠拢。</li>
|
||
<li><strong>第三阶段 (2028+)：成熟与国际化期</strong> - 创新产品寻求国际化，AI赋能的“数字中药”成核心竞争力。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="bento-item">
|
||
<h2 class="bento-title">潜在风险与挑战</h2>
|
||
<div class="bento-content">
|
||
<ul>
|
||
<li><strong>技术风险</strong>：跨界研发挑战巨大，临床试验失败率高，AI融合效果待验证。</li>
|
||
<li><strong>商业化风险</strong>：医保谈判、医院准入、与大型药企竞争激烈。</li>
|
||
<li><strong>资本风险</strong>：创新药研发是“烧钱”游戏，可能拖累业绩。</li>
|
||
<li><strong>政策风险</strong>：医保控费大趋势不变，创新药亦可能面临集采压力。</li>
|
||
<li><strong>竞争风险</strong>：热门靶点（如GLP-1）扎堆，或导致行业内卷。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Section 4: In-depth Company Analysis -->
|
||
<section>
|
||
<div class="text-center mb-8">
|
||
<h2 class="section-title">深度剖析：核心参与者</h2>
|
||
<p class="text-gray-400 max-w-3xl mx-auto">中药企业正利用稳健现金流，通过自主研发、合作开发、外延并购等方式，系统性布局化药、生物药及细胞/基因治疗等前沿领域，转型路径日渐清晰。</p>
|
||
</div>
|
||
<div class="glass-card overflow-x-auto">
|
||
<table class="glass-table">
|
||
<thead>
|
||
<tr>
|
||
<th class="w-1/6">股票</th>
|
||
<th class="w-1/4">转型逻辑</th>
|
||
<th class="w-7/12">核心创新项目管线</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<!-- Stock Data will be injected here by the script -->
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</section>
|
||
</main>
|
||
</div>
|
||
|
||
<script>
|
||
document.addEventListener('alpine:init', () => {
|
||
// Chart Data
|
||
const approvalChartData = {
|
||
years: ['2020', '2021', '2022', '2023', '2024', '2025 Q1'],
|
||
ind: [17, 44, 39, 54, 80, 20],
|
||
nda: [6, 10, 10, 8, 11, 13]
|
||
};
|
||
|
||
var chartDom = document.getElementById('approval-chart');
|
||
var myChart = echarts.init(chartDom);
|
||
var option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
backgroundColor: 'rgba(0, 0, 0, 0.7)',
|
||
borderColor: '#374151',
|
||
textStyle: { color: '#E5E7EB' }
|
||
},
|
||
legend: {
|
||
data: ['创新中药IND受理量', '创新中药NDA受理量'],
|
||
textStyle: { color: '#9CA3AF' }
|
||
},
|
||
grid: {
|
||
left: '3%', right: '4%', bottom: '3%', containLabel: true
|
||
},
|
||
xAxis: {
|
||
type: 'category',
|
||
boundaryGap: false,
|
||
data: approvalChartData.years,
|
||
axisLine: { lineStyle: { color: '#4B5563' } }
|
||
},
|
||
yAxis: {
|
||
type: 'value',
|
||
axisLine: { lineStyle: { color: '#4B5563' } },
|
||
splitLine: { lineStyle: { color: '#374151', type: 'dashed' } }
|
||
},
|
||
series: [
|
||
{
|
||
name: '创新中药IND受理量',
|
||
type: 'line',
|
||
smooth: true,
|
||
data: approvalChartData.ind,
|
||
itemStyle: { color: '#38BDF8' },
|
||
lineStyle: {
|
||
width: 3,
|
||
shadowColor: 'rgba(56, 189, 248, 0.5)',
|
||
shadowBlur: 10
|
||
}
|
||
},
|
||
{
|
||
name: '创新中药NDA受理量',
|
||
type: 'line',
|
||
smooth: true,
|
||
data: approvalChartData.nda,
|
||
itemStyle: { color: '#FB7185' },
|
||
lineStyle: {
|
||
width: 3,
|
||
shadowColor: 'rgba(251, 113, 133, 0.5)',
|
||
shadowBlur: 10
|
||
}
|
||
}
|
||
]
|
||
};
|
||
myChart.setOption(option);
|
||
window.addEventListener('resize', () => myChart.resize());
|
||
|
||
// Stock Data
|
||
const stockData = [
|
||
{
|
||
"stock": "众生药业",
|
||
"reason": "通过控股子公司众生睿创，公司正在开发针对减重/降糖、新冠、流感和MASH的创新药物。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "控股子公司众生睿创 (持股77.83%)", "转型领域": "减重/降糖", "品种": "RAY1225注射液", "靶点": "GLP-1/GIP双靶点", "进度": "III期临床进行中 (2025年5月减重及降糖III期均启动)" },
|
||
{ "转型主体": "控股子公司众生睿创 (持股77.83%)", "转型领域": "新冠", "品种": "来瑞特韦片", "靶点": "新冠病毒3CL蛋白酶抑制剂", "进度": "已上市 (2023年3月)" },
|
||
{ "转型主体": "控股子公司众生睿创 (持股77.83%)", "转型领域": "流感", "品种": "昂拉地韦片", "靶点": "RNA聚合酶PB2蛋白抑制剂", "进度": "已上市 (2025年5月)" },
|
||
{ "转型主体": "控股子公司众生睿创 (持股77.83%)", "转型领域": "MASH", "品种": "ZSP1601片", "靶点": "泛磷酸二酯酶 (PDE) 抑制剂", "进度": "IIb期临床进行中" }
|
||
]
|
||
},
|
||
"stock_code": "002317"
|
||
},
|
||
{
|
||
"stock": "康缘药业",
|
||
"reason": "通过全资子公司江苏中新医药，公司正在开发针对减重/降糖、视神经损伤、神经营养性角膜炎和术后疼痛的创新药物。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "全资子公司江苏中新医药", "转型领域": "减重/降糖", "品种": "ZX2010注射液", "靶点": "GLP-1/GIP双靶点", "进度": "I期临床完成，准备开展II期临床" },
|
||
{ "转型主体": "全资子公司江苏中新医药", "转型领域": "减重/降糖", "品种": "ZX2021注射液", "靶点": "GLP-1/GIP/GCG三靶点", "进度": "II期临床启动 (2025年4月)" },
|
||
{ "转型主体": "全资子公司江苏中新医药", "转型领域": "视神经损伤", "品种": "ZX1305注射液", "靶点": "重组人神经生长因子", "进度": "完成IIa期临床" },
|
||
{ "转型主体": "全资子公司江苏中新医药", "转型领域": "神经营养性角膜炎", "品种": "ZX1305E滴眼液", "靶点": "重组人神经生长因子", "进度": "II期临床进行中" },
|
||
{ "转型主体": "全资子公司江苏中新医药", "转型领域": "术后疼痛", "品种": "苯胺洛芬注射液", "靶点": "抑制前列腺素合成", "进度": "已提交上市申请 (24年7月)" }
|
||
]
|
||
},
|
||
"stock_code": "600557"
|
||
},
|
||
{
|
||
"stock": "以岭药业",
|
||
"reason": "通过全资子公司以岭万洲，公司正在开发针对急性髓性白血病(AML)和急性缺血性脑卒中的创新药物。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "全资子公司以岭万洲", "转型领域": "急性髓性白血病 (AML)", "品种": "XY0206 (口服)", "靶点": "FLT3抑制剂", "进度": "I期临床进行中 (2023年10月)" },
|
||
{ "转型主体": "全资子公司以岭万洲", "转型领域": "急性缺血性脑卒中", "品种": "XY03-EA片", "靶点": "NBP的新型衍生物，氧自由基清除", "进度": "IIb期临床进行中" }
|
||
]
|
||
},
|
||
"stock_code": "002603"
|
||
},
|
||
{
|
||
"stock": "云南白药",
|
||
"reason": "通过子公司云核医药及外部引进，公司正在布局核药和生物药领域，针对前列腺癌、实体瘤等适应症。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "全资子公司云核医药", "转型领域": "前列腺癌/子宫肌瘤", "品种": "G201胶囊", "靶点": "促性腺激素释放激素 (GnRH)", "进度": "筹备II期临床" },
|
||
{ "转型主体": "全资子公司云核医药", "转型领域": "前列腺癌PET成像", "品种": "INR101注射液 (核药)", "靶点": "前列腺特异性膜抗原 (PSMA)", "进度": "III期临床进行中 (25年5月首例入组)" },
|
||
{ "转型主体": "全资子公司云核医药", "转型领域": "前列腺癌治疗", "品种": "INR102注射液 (核药)", "靶点": "前列腺特异性膜抗原 (PSMA)", "进度": "25年4月IND获批 (I/IIa期)" },
|
||
{ "转型主体": "从圆祥生技引进", "转型领域": "实体瘤", "品种": "B1962注射液 (双抗)", "靶点": "PD-L1/VEGF双抗", "进度": "I期临床进行中 (24年11月)" }
|
||
]
|
||
},
|
||
"stock_code": "000538"
|
||
},
|
||
{
|
||
"stock": "天士力",
|
||
"reason": "通过自主研发、合作开发、外部引进等多种方式，公司在NASH、实体瘤(ADC)、细胞治疗(干细胞、CAR-T)、罕见病、抗抑郁等多个前沿领域进行创新转型。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "全资子公司天士力生物", "转型领域": "NASH/糖尿病", "品种": "B1344注射液", "靶点": "FGF21", "进度": "Ia期试验已完成统计报告" },
|
||
{ "转型主体": "从Sutro Biopharma引进", "转型领域": "晚期实体瘤", "品种": "STRO-002注射液 (ADC)", "靶点": "FRα ADC", "进度": "I期临床 (国内) 完成全部受试者入组" },
|
||
{ "转型主体": "与上海市东方医院合作", "转型领域": "CABG指征的慢性缺血性心肌病导致的慢性心力衰竭", "品种": "B2278注射液", "靶点": "人脐带间充质干细胞注射液", "进度": "I期临床进行中" },
|
||
{ "转型主体": "自主研发", "转型领域": "急性缺血性脑卒中", "品种": "NR-20201注射液", "靶点": "同种异体脂肪来源间充质基质细胞", "进度": "24年10月美国IND获批，25年3月国内IND获批" },
|
||
{ "转型主体": "与北京神经外科研究所合作开发", "转型领域": "复发胶质母细胞瘤", "品种": "P134细胞注射液 (CAR-T)", "靶点": "靶向CD44、CD133的自体CAR-T", "进度": "25年4月IND获批" },
|
||
{ "转型主体": "与法国Pharnext合资天士力基因网络 (持股65%)", "转型领域": "腓骨肌萎缩症1A型 (CMT1A)", "品种": "PXT3003", "靶点": "PMP22", "进度": "25年4月上市申请获受理" },
|
||
{ "转型主体": "全资子公司天士力帝益", "转型领域": "肿瘤", "品种": "TSL-1502胶囊", "靶点": "PARP抑制剂", "进度": "I期临床进行中" },
|
||
{ "转型主体": "自主研发", "转型领域": "抗抑郁", "品种": "JS1-1-01片", "靶点": "5-羟色胺-去甲肾上腺素-多巴胺三重再摄取抑制剂 (SNDRIs)", "进度": "II期临床完成全部受试者出组" }
|
||
]
|
||
},
|
||
"stock_code": "600535"
|
||
},
|
||
{
|
||
"stock": "济川药业",
|
||
"reason": "通过合作与参股方式，公司正在向流感、银屑病/特应性皮炎/COPD等创新药领域拓展。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "与南京征祥医药合作并参股", "转型领域": "流感", "品种": "玛硒洛沙韦片 (ZX-7101A)", "靶点": "聚合酶酸性蛋白 (PA) 抑制剂", "进度": "2024年2月上市申请获受理" },
|
||
{ "转型主体": "与恒翼生物独家合作", "转型领域": "银屑病/特应性皮炎/COPD", "品种": "HPP737胶囊", "靶点": "PDE4抑制剂", "进度": "中重度斑块状银屑病II期临床进行中" }
|
||
]
|
||
},
|
||
"stock_code": "600566"
|
||
},
|
||
{
|
||
"stock": "佐力药业",
|
||
"reason": "通过与参股公司凌意生物的战略合作，公司正在布局帕金森症、威尔逊症、戈谢症等罕见病的基因治疗领域。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "参股公司凌意生物战略合作", "转型领域": "帕金森症", "品种": "LY-N001", "靶点": "GBA1基因", "进度": "IND申请中" },
|
||
{ "转型主体": "参股公司凌意生物战略合作", "转型领域": "威尔逊症", "品种": "LY-M003", "靶点": "ATP7B基因", "进度": "I期临床进行中" },
|
||
{ "转型主体": "参股公司凌意生物战略合作", "转型领域": "I/III型戈谢症", "品种": "LY-M001", "靶点": "GBA1基因", "进度": "I/II期临床进行中，2024年8月首例患者接受治疗" }
|
||
]
|
||
},
|
||
"stock_code": "300181"
|
||
},
|
||
{
|
||
"stock": "珍宝岛",
|
||
"reason": "通过参股浙江特瑞思药业，公司涉足抗CD20-ADC药物的开发，用于治疗非霍奇金淋巴瘤。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "参股公司浙江特瑞思药业 (持股17.02%)", "转型领域": "非霍奇金淋巴瘤", "品种": "TRS005", "靶点": "抗CD20-ADC", "进度": "关键单臂注册II期进行中 (24年3月，同时纳入突破性治疗品种)" }
|
||
]
|
||
},
|
||
"stock_code": "603567"
|
||
},
|
||
{
|
||
"stock": "华纳药厂",
|
||
"reason": "通过控股子公司致根医药，公司正在开发抗抑郁和治疗中重度斑块状银屑病的创新药物。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "控股子公司致根医药 (持股40%)", "转型领域": "抗抑郁", "品种": "ZG-001胶囊", "靶点": "BDNF-TrkB", "进度": "IIa期临床进行中，预计2025完成" },
|
||
{ "转型主体": "控股子公司致根医药 (持股40%)", "转型领域": "中重度斑块状银屑病", "品种": "ZG-002片", "靶点": "TYK2变构抑制剂", "进度": "I期临床进行中，预计2025完成" }
|
||
]
|
||
},
|
||
"stock_code": "688799"
|
||
},
|
||
{
|
||
"stock": "九芝堂",
|
||
"reason": "通过控股子公司九芝堂美科，公司正在开发人骨髓间充质干细胞注射液，用于治疗缺血性脑卒中、自身免疫性肺泡蛋白沉积症和孤独症谱系障碍。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "控股子公司九芝堂美科 (北京) 细胞技术有限公司 (持股98.61%)", "转型领域": "缺血性脑卒中", "品种": "人骨髓间充质干细胞注射液", "进度": "IIa期临床进行中，截至25年4月已完成31例受试者入组" },
|
||
{ "转型主体": "控股子公司九芝堂美科 (北京) 细胞技术有限公司 (持股98.61%)", "转型领域": "自身免疫性肺泡蛋白沉积症", "品种": "人骨髓间充质干细胞注射液", "进度": "IIa期临床进行中，截至25年4月已完成8例受试者入组" },
|
||
{ "转型主体": "控股子公司九芝堂美科 (北京) 细胞技术有限公司 (持股98.61%)", "转型领域": "孤独症谱系障碍", "品种": "人骨髓间充质干细胞注射液", "进度": "25年3月IND获批" }
|
||
]
|
||
},
|
||
"stock_code": "000989"
|
||
},
|
||
{
|
||
"stock": "羚锐制药",
|
||
"reason": "通过控股子公司银谷制药，公司开发了用于治疗过敏性鼻炎的创新药物。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "控股子公司银谷制药 (持股90%)", "转型领域": "过敏性鼻炎", "品种": "苯环喹溴铵鼻喷雾剂", "靶点": "选择性M1/M3胆碱能受体拮抗剂", "进度": "变应性鼻炎适应症已上市" }
|
||
]
|
||
},
|
||
"stock_code": "600285"
|
||
},
|
||
{
|
||
"stock": "桂林三金",
|
||
"reason": "通过孙公司宝船生物，公司正在开发针对晚期实体瘤和特发性肺纤维化的单克隆抗体药物。",
|
||
"其他标签": {
|
||
"创新项目": [
|
||
{ "转型主体": "孙公司宝船生物", "转型领域": "晚期实体瘤", "品种": "BC006注射液 (单抗)", "靶点": "巨噬细胞集落刺激因子1受体 (CSF-1R)", "进度": "I期临床试验即将完成" },
|
||
{ "转型主体": "孙公司宝船生物", "转型领域": "特发性肺纤维化", "品种": "BC006注射液 (单抗)", "靶点": "巨噬细胞集落刺激因子1受体 (CSF-1R)", "进度": "25年5月IND获批" }
|
||
]
|
||
},
|
||
"stock_code": "002275"
|
||
}
|
||
];
|
||
|
||
const tableBody = document.querySelector('table.glass-table tbody');
|
||
stockData.forEach(item => {
|
||
let projectsHtml = '<ul>';
|
||
if (item['其他标签'] && item['其他标签']['创新项目']) {
|
||
item['其他标签']['创新项目'].forEach(proj => {
|
||
projectsHtml += `
|
||
<li>
|
||
<strong class="text-sky-300">${proj['品种']}</strong> (${proj['转型领域']})
|
||
<p class="text-xs text-gray-400 pl-2">
|
||
<strong>主体:</strong> ${proj['转型主体']}<br>
|
||
<strong>靶点:</strong> ${proj['靶点']}<br>
|
||
<strong>进度:</strong> ${proj['进度']}
|
||
</p>
|
||
</li>
|
||
`;
|
||
});
|
||
}
|
||
projectsHtml += '</ul>';
|
||
|
||
const row = `
|
||
<tr>
|
||
<td>
|
||
<a href="https://valuefrontier.cn/company?scode=${item.stock_code}" target="_blank" class="stock-link">
|
||
${item.stock} (${item.stock_code})
|
||
</a>
|
||
</td>
|
||
<td class="text-gray-300 text-sm">${item.reason}</td>
|
||
<td>${projectsHtml}</td>
|
||
</tr>
|
||
`;
|
||
tableBody.innerHTML += row;
|
||
});
|
||
});
|
||
</script>
|
||
|
||
</body>
|
||
</html> |